| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Molgramostim 400 microgram powder for solution for injection vial |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Molgramostim 400 microgram powder for solution for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Octreotide (as octreotide acetate) 30 mg powder for suspension for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Octreotide (as octreotide acetate) 30 mg powder for suspension for injection vial |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Etoposide (as etoposide phosphate) 100 mg powder for solution for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Etoposide (as etoposide phosphate) 100 mg powder for solution for injection vial |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| somatropin (rbe) 1,3 milligram/injektionsflaska, pulver till injektionsvätska |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| somatropin (rbe) 1,3 milligram/injektionsflaska, pulver till injektionsvätska |
Has presentation strength denominator unit (attribute) |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Glatiramer acetate 20 mg powder for solution for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Glatiramer acetate 20 mg powder for solution for injection vial |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Epoprostenol (as epoprostenol sodium) 1.5 mg powder for solution for injection vial |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Epoprostenol (as epoprostenol sodium) 1.5 mg powder for solution for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| somatropin (rmc) 1,33 milligram/injektionsflaska, pulver till injektionsvätska |
Has presentation strength denominator unit (attribute) |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| somatropin (rmc) 1,33 milligram/injektionsflaska, pulver till injektionsvätska |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely teicoplanin 200 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely teicoplanin 200 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| somatropin (rmc) 3,33 milligram/injektionsflaska, pulver till injektionsvätska |
Has presentation strength denominator unit (attribute) |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| somatropin (rmc) 3,33 milligram/injektionsflaska, pulver till injektionsvätska |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely teicoplanin 400 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Product containing precisely teicoplanin 400 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely epoprostenol (as epoprostenol sodium) 500 microgram/1 vial powder for conventional release solution for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Product containing precisely epoprostenol (as epoprostenol sodium) 500 microgram/1 vial powder for conventional release solution for injection (clinical drug) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Interferon alfa-2b 1 million unit powder for solution for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Interferon alfa-2b 1 million unit powder for solution for injection vial |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely sargramostim 250 microgram/1 vial powder for conventional release solution for injection (clinical drug) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely sargramostim 250 microgram/1 vial powder for conventional release solution for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Product containing precisely tenoxicam 20 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Product containing precisely tenoxicam 20 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely etanercept 50 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely etanercept 50 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| indometacin (som indometacinnatriumtrihydrat) 1 milligram/injektionsflaska, pulver till injektionsvätska |
Has presentation strength denominator unit (attribute) |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| indometacin (som indometacinnatriumtrihydrat) 1 milligram/injektionsflaska, pulver till injektionsvätska |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely clavulanic acid (as clavulanate potassium) 200 milligram and ticarcillin (as ticarcillin disodium) 3 gram/1 vial powder for conventional release solution for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Product containing precisely clavulanic acid (as clavulanate potassium) 200 milligram and ticarcillin (as ticarcillin disodium) 3 gram/1 vial powder for conventional release solution for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
2 |
| Product containing precisely clavulanic acid (as clavulanate potassium) 200 milligram and ticarcillin (as ticarcillin disodium) 3 gram/1 vial powder for conventional release solution for injection (clinical drug) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| peginterferon alfa-2b 50 mikrogram, pulver till injektionsvätska, lösning, flaska |
Has presentation strength denominator unit (attribute) |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| peginterferon alfa-2b 50 mikrogram, pulver till injektionsvätska, lösning, flaska |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Epirubicin hydrochloride 20 mg powder for solution for injection vial |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Epirubicin hydrochloride 20 mg powder for solution for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Coagulation factor XIII 1250 unit powder for solution for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Coagulation factor XIII 1250 unit powder for solution for injection vial |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely epirubicin hydrochloride 50 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely epirubicin hydrochloride 50 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Product containing precisely coagulation factor XIII 250 unit/1 vial powder for conventional release solution for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Product containing precisely coagulation factor XIII 250 unit/1 vial powder for conventional release solution for injection (clinical drug) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Topotecan (as topotecan hydrochloride) 1 mg powder for solution for injection vial |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Topotecan (as topotecan hydrochloride) 1 mg powder for solution for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| peginterferon alfa-2b 120 mikrogram, pulver till injektionsvätska, lösning, flaska |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| peginterferon alfa-2b 120 mikrogram, pulver till injektionsvätska, lösning, flaska |
Has presentation strength denominator unit (attribute) |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Galactose 2.49 g and palmitic acid 2.5 mg powder for suspension for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
2 |
| Galactose 2.49 g and palmitic acid 2.5 mg powder for suspension for injection vial |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Galactose 2.49 g and palmitic acid 2.5 mg powder for suspension for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Trastuzumab 150 mg powder for solution for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Trastuzumab 150 mg powder for solution for injection vial |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Galactose 3.99 g and palmitic acid 4 mg powder for suspension for injection vial |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Galactose 3.99 g and palmitic acid 4 mg powder for suspension for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
2 |
| Galactose 3.99 g and palmitic acid 4 mg powder for suspension for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Pentostatin 10 mg powder for solution for injection vial |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Pentostatin 10 mg powder for solution for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Product containing precisely glucagon hydrochloride 1 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely glucagon hydrochloride 1 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Product containing precisely etanercept 25 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Product containing precisely etanercept 25 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Ganciclovir (as ganciclovir sodium) 500 mg powder for solution for injection vial |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Ganciclovir (as ganciclovir sodium) 500 mg powder for solution for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Product containing precisely gonadorelin (as gonadorelin hydrochloride) 100 microgram/1 vial powder for conventional release solution for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Product containing precisely gonadorelin (as gonadorelin hydrochloride) 100 microgram/1 vial powder for conventional release solution for injection (clinical drug) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely mitomycin 40 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely mitomycin 40 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Product containing precisely molgramostim 150 microgram/1 vial powder for conventional release solution for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Product containing precisely molgramostim 150 microgram/1 vial powder for conventional release solution for injection (clinical drug) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely romiplostim 250 microgram/1 vial powder for conventional release solution for injection (clinical drug) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely romiplostim 250 microgram/1 vial powder for conventional release solution for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Flucloxacillin (as flucloxacillin sodium) 250 mg powder for solution for injection vial |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Flucloxacillin (as flucloxacillin sodium) 250 mg powder for solution for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Product containing precisely mitomycin 10 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely mitomycin 10 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| meropenem (som meropenemtrihydrat) 500 milligram/injektionsflaska, pulver till injektionsvätska |
Has presentation strength denominator unit (attribute) |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| meropenem (som meropenemtrihydrat) 500 milligram/injektionsflaska, pulver till injektionsvätska |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Mitomycin 2 mg powder for solution for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Mitomycin 2 mg powder for solution for injection vial |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Infliximab 100 mg powder for solution for injection vial |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Infliximab 100 mg powder for solution for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Imiglucerase 200 unit powder for solution for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Imiglucerase 200 unit powder for solution for injection vial |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Piperacillin (as piperacillin sodium) 2 g and tazobactam (as tazobactam sodium) 250 mg powder for solution for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Piperacillin (as piperacillin sodium) 2 g and tazobactam (as tazobactam sodium) 250 mg powder for solution for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
2 |
| Piperacillin (as piperacillin sodium) 2 g and tazobactam (as tazobactam sodium) 250 mg powder for solution for injection vial |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| flukonazol 50 mg/25 ml, infusionsvätska, lösning, flaska |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| atrakuriumbesylat 250 mg/25 ml, injektionsvätska, lösning, flaska |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| fluorouracil (som fluorouracilnatrium) 2,5 g/100 ml, injektionsvätska, lösning, flaska |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| pamidronatdinatrium 60 mg/20 ml, injektionsvätska, lösning, flaska |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| fluorouracil (som fluorouracilnatrium) 250 mg/10 ml, injektionsvätska, lösning, flaska |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| pamidronatdinatrium 90 mg/30 ml, injektionsvätska, lösning, flaska |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| dobutamin (som dobutaminhydroklorid) 250 mg/20 ml, infusionsvätska, lösning, flaska |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| flufenazindekanoat 250 mg/10 ml, injektionsvätska, lösning, flaska |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| doxorubicinhydroklorid 200 mg/100 ml, injektionsvätska, lösning, flaska |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| ekulizumab 300 mg/30 ml, injektionsvätska, lösning, flaska |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| buserelin (som buserelinacetat) 5,5 mg/5,5 ml, injektionsvätska, lösning, flaska |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| edrofoniumklorid 150 mg/15 ml, injektionsvätska, lösning, flaska |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| epirubicinhydroklorid 200 mg/100 ml, infusionsvätska, lösning, flaska |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
FHIR